Click here to close now.




















Welcome!

News Feed Item

Antibacterial Drugs: World Industry and Market Prospects 2014-2024

LONDON, March 11, 2014 /PRNewswire/ --

Antibacterials - new analysis showing business trends, R&D, and revenue forecasts

What is the future of medicines treating bacterial infections? For those drugs you get new sales predictions, also exploring research and development. Those treatments hold high potentials. There you assess results, progress, therapies, and opportunities.

Knowledge facilitates success. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. There you stay ahead in data on microbial diseases, finding commercial prospects to benefit your influence.

Read on to explore antibiotics for human healthcare, seeing how high sales can go.

Forecasts to 2024 and other analyses explain and predict that antimicrobials market

Why miss data you need? Why struggle to find it, or fall behind? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find recent results, growth rates, market shares, and discussions.

Also you see the potential of research and development. That study gives 126 tables, 102 charts, and interviews with three companies.

There you assess the future of antibacterials, hearing how patients, doctors, and pharma companies can benefit. You stay ahead, then, finding where money lies, assessing the most lucrative selling prospects.

And the following sections show how that new investigation helps your research, analyses and decisions. See there how you could benefit your authority and save time, staying ahead.

Sales predictions for the world antibiotics market and submarkets

What is that biomedical industry's potential? What are the secrets of its progress? Discover in our report overall world revenue to 2024 for those bacteria-treating agents.

Also find individual revenue predictions to 2024 for six therapeutic submarkets at world level:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other treatments for bacterial infections.

There you explore prospects from 2014, hearing where you could profit from novel agents and generic drugs (generics). Investigate competition, developments, and rising sales.

That study also predicts and discusses leading medicines' sales potentials

To see an exec summary of this report please email Sara Peerun on [email protected] .

Revenue predictions for leading and expected products

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 43 products - marketed agents and drugs awaiting launch.

You assess top products, including these:
• Zyvox
• Augmentin
• Cubicin
• Generic amoxicillin
• Avelox.

There you find medicines and years with highest predicted sales. Also you examine competitors and get an understanding of recent challenges, trends, and outlooks.

For that overall market, the report also shows geographical revenue predictions.

National markets - what are the demands for antibacterial therapies?

In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for a regional block and 12 national markets:
United States (US)
• European Union (EU) - also with separate forecasts for France, Germany, the UK, Italy, and Spain (EU5 countries)
Japan
South Korea
• The BRIC nations - Brazil, Russia, India, and China.

For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for fighting bacterial infections, also assessing the expected financial gains.

And what events change that industry? Our work shows you, discussing trends, challenges and opportunities.

Market forces and issues - what affects antibiotic developers, producers and sellers?

The report shows you issues and events affecting that industry and market from 2014, including these:
• Antibacterial drug consumption statistics at national level
• Incidences of urinary tract, skin, and respiratory tract infections from bacteria
• Generic competition for leading brands - effects of patent expiries
• Prescription control to reduce bacterial resistance, including that of methicillin-resistant S. aureus (MRSA)
• Encouraging antibiotic drug discovery and development - push and pull incentives, inc. public-private collaborations.

And you explore these influences, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other new drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies.

Discover what the future holds. There you explore political, economic, social, and technological questions. See, too, how R&D lets companies benefit patients.

There you find what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of top companies and potential for market growth - what revenue is possible?

From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from bacteria-treating drugs.

So what happens next? Our study predicts that world market will reach $42.75bn in 2018, with further expansion to 2024.

That work also explores activities and potentials of these companies, among others:
• Pfizer
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• Bayer
• Cubist Pharmaceuticals
• Daiichi Sankyo.

R&D in that industry holds strengths, and from 2014 opportunity arises. Patients, payers, and companies will benefit. Discover what is possible.

And you will be able to see how that market can perform, staying ahead in knowledge and benefiting your reputation for commercial insight.

Ways Antibacterial Drugs: World Industry and Market Prospects 2014-2024  helps you

In particular, that new investigation gives you this information:
• Revenues there to 2024 at world level, for 6 submarkets, and 43 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Knowledge found nowhere else, helping your searches, analyses, and planning

Our study gives independent data. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.

With that original research and analysis you are less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort. And also help your plans, decisions, influence, and competing.

The new report shows commercial potentials of medicines for human infective diseases. There you explore trends and R&D, and investigate future sales. So avoid missing out - please order now.

Companies Listed in this report:
Abbott
AbbVie
Achaogen
ACS Dobfar
Actavis
Actelion Pharmaceuticals
Aeras
Affinium Pharmaceuticals
Alcon
Alkem Laboratories
Allied Pharma
AmpliPhi Bioscience
Apotex
APP Pharmaceuticals
Aptalis Pharma
Aquapharm Biodiscovery
Aradigm
Aridis Pharmaceuticals
Arsanis Biosciences
Ascend Therapeutics
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Basilea Pharmaceutica
Bayer
Biomax Biotechnics
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA)
Brazilian National Health Surveillance Agency
Cadila Healthcare
Calixa Therapeutics
Cardeas Pharma
Cellceutix
Cempra Pharmaceuticals
Centers for Disease Control and Prevention (CDC)
Chinese Ministry of Health
Chiron
Cipla
Claris Lifesciences
Clinigen
Cornerstone Therapeutics
Corona Remedies
Critical Therapeutics
Cubist Pharmaceuticals
Curetis
Daiichi Sankyo
Dainippon Sumitomo
Destiny Pharma
Discuva
Dr. Reddy's Laboratories
Duke University
Durata Therapeutics
Eli Lilly
Emcure Pharmaceuticals
Eros Pharma
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Fitch Ratings Agency
Food and Drug Administration (US FDA)
Forest Laboratories
Fraunhofer-Gesellschaft
Furiex Pharmaceuticals
Gate Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Generics
GlycoVaxyn
Guangdong BeiKang
Hetero
Hi Tech Pharma
Hikma Pharmaceuticals
Hospira
Indian Ministry of Health and Family Welfare
Insmed
Intercell
Itochu Chemical Frontier
Janssen Pharmaceutica
Japanese Ministry of Health Labor and Welfare
Johns Hopkins University School of Medicine
Johnson & Johnson
KaloBios
Kenta Biotech
Kuhnil Pharm
Lupin
Macleod Pharmaceuticals
Medicines and Healthcare Products Regulatory Agency
Medicis
MedImmune
Medison Pharma
Medsintez
Meiji Seika Pharma
Melinta Therapeutics
Merck & Co.
MerLion Pharmaceuticals
Microlabs
MicuRx Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW, Japan)
Mpex Pharmaceuticals
Mylan
Nabriva Therapeutics
Nalneva
National Institute for Health and Clinical Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Neiss Labs
Nektar Therapeutics
Nichi-Iko Pharmaceuticals
Nipro Pharma
Novacta Biosystems
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Healthcare
Paratek Pharmaceuticals
Pearl Therapeutics
Pfizer
Phico Therapeutics
Piramal Healthcare,
Plenus Pharmaceuticals
Pliva
Polyphor
Procarta Biosystems
Procter & Gamble
Ranbaxy Labs
Redx Pharma
Roche
Roxane
R-Pharma
RQx Pharmaceutical
Sagent Pharmaceuticals
Sandoz
Sanofi
Sanofi Pasteur
Savara Pharmaceuticals
Sawai Pharmaceutical
Sequella
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shionogi
Shire
Sidmak Labs
Sistema Nacional de Gerenciamento de Produtos Controlados
Solitaire Pharmacia
Specialised Therapeutics
Sunovion Pharma
TaiGen Biotechnology
Taisho Pharmaceuticals
Taiyo Yakuhin
Takeda
TAP Holdings
Targanta Therapeutics
Tedec-Meiji Farma
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Torrent Pharmaceuticals
Trius Therapeutics
TTY Biopharma
Unichem Laboratories
University of Leicester
University of Michigan
US Department of Health
Valeant Pharmaceuticals
Vansen Pharma
Vicuron
ViroPharma
Warner Chilcott
Watson
Wockhardt
World Health Organization (WHO)
Zhejiang Medicine Company
Zuelig Pharma
Zydus Pharmaceuticals

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel : +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1215/Antibacterial-Drugs-World-Industry-and-Market-Prospects-2014-2024


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A producer of the first smartphones and tablets, presenter Lee M. Williams will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. In his session at @ThingsExpo, Lee Williams, COO of ETwater, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ET...
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...